SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition

SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition

Abstract Despite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely the result of compensatory pathway activation mechanisms. However, the underlyi...

Full description

Bibliographic Details
Main Authors: Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J. Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan Zea Tan, Janina E. E. Tirnitz-Parker, Jean Paul Thiery, Hiromichi Ebi, Alan Prem Kumar, Pieter Johan Adam Eichhorn
Format: Article
Language:English
Published: Nature Portfolio 2023-12-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00486-6

Internet

https://doi.org/10.1038/s41698-023-00486-6

Similar Items